文献速递肝胆胰外科围术期管理与 ERAS

合并大血管侵犯及癌栓肝细胞癌根治切除术后疗效与围术期治疗策略分析

[Analysis of clinical efficacy and perioperative treatment strategies after radical resection for hepatocellular carcinoma with major vascular invasion and tumor thrombus].
PubMed 文献 · Zhonghua Wai Ke Za Zhi · 2025-01-01

本研究回顾性分析387例合并大血管侵犯及癌栓的肝细胞癌手术患者,R0切除率92.8%,R0切除患者中位OS 19.8个月。术后辅助治疗组中位OS 53.0个月,显著优于未行辅助治疗组的13.7个月(P<0.01)。多因素分析显示肿瘤最大径、术后辅助治疗和复发后处理方式是OS的独立影响因素。

要点

  • 合并大血管侵犯及癌栓HCC患者经严格筛选后以手术为主的综合治疗可获益。
  • 术后辅助治疗显著降低复发并延长生存,为独立影响因素。
  • 术前新辅助治疗对总体生存无显著影响(P>0.05)。

核心结论

  • 合并大血管侵犯及癌栓的HCC患者经严格筛选评估后,以手术切除为主的综合治疗可使生存获益。
  • 术后辅助治疗可减少术后肿瘤复发,延长患者生存时间。

研究设计与样本

  • 本研究为回顾性病例系列研究,纳入2010年1月至2022年12月南京医科大学第一附属医院肝胆中心行肝切除的387例HCC患者。
  • 男326例(84.2%),女61例(15.8%),年龄M(IQR)54(16)岁(范围16~82岁)。
  • 大血管侵犯无癌栓119例(30.7%),合并血管癌栓268例(69.3%)。

主要发现

  • 387例中R0切除359例(92.8%),R1或R2切除28例(7.2%)。
  • 354例R0切除患者中位OS 19.8个月,1、3、5年OS率分别为63.3%、35.1%、22.4%;中位RFS 5.6个月,1、3、5年RFS率分别为34.0%、18.0%、14.4%。
  • 术前新辅助治疗患者中位OS 26.0个月,1、3、5年OS率分别为75.5%、48.4%、32.5%,术前是否行新辅助治疗对OS无显著影响(P>0.05)。
  • 术后辅助治疗组中位OS 53.0个月,1、3、5年OS率分别为87.9%、59.2%、34.8%;未行术后辅助治疗组中位OS 13.7个月,1、3、5年OS率分别为56.7%、31.7%、22.4%(P<0.01)。
  • 术后辅助治疗组中位RFS 11.6个月,1、3、5年RFS率分别为49.6%、29.8%、26.8%;未行术后辅助治疗组中位RFS 4.2个月,1、3、5年RFS率分别为29.2%、16.1%、12.5%(P<0.01)。

关键数值与推荐

  • 多因素分析显示肿瘤最大径、术后辅助治疗和复发后处理方式是合并大血管侵犯及癌栓HCC患者OS的独立影响因素(P值均<0.05)。
  • 患者年龄、手术方式、术后辅助治疗是合并大血管侵犯及癌栓HCC患者RFS的独立影响因素(P值均<0.05)。

临床怎么用

  • 对合并大血管侵犯及癌栓的HCC患者应严格筛选评估后行以手术为主的综合治疗。
  • 术后应重视辅助治疗以降低复发、延长生存。
  • 复发后积极处理可能改善总体生存。

局限性

  • 本研究为单中心回顾性病例系列研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To evaluate the clinical outcomes of radical resection and perioperative management strategies in hepatocellular carcinoma (HCC) patients with major vascular invasion and tumor thrombus. Methods: This is a retrospective case series study. From January 2010 to December 2022,clinicopathological data of 387 HCC patients who underwent liver resection at the Hepatobiliary Center of the First Affiliated Hospital of Nanjing Medical University were retrospectively analyzed. In the cohort,there were 326 males (84.2%) and 61 females (15.8%),with an age (M(IQR)) of 54(16) years (range: 16 to 82 years). One hundred and nineteen patients (30.7%) had macrovascular invasion without thrombus and 268 patients(69.3%) had macrovascular thrombus. Categorical variables were presented as frequencies (percentages). Survival rates were calculated using life-table analysis,and Kaplan-Meier curves were employed to depict overall survival(OS) and recurrence-free survival (RFS). Independent prognostic factors were identified by univariate and multivariate Cox regression. Results: Among 387 patients,R0 resection was achieved in 359 cases (92.8%),with R1 or R2 resection in 28 cases (7.2%). Excluding in-hospital deaths,the 354 R0-resected patients had a median OS of 19.8 months, with 1-, 3-, and 5-year OS rates were 63.3%, 35.1%, and 22.4%, respectively; median RFS was 5.6 months,and 1-, 3-, and 5-year RFS was 34.0%,18.0%,and 14.4%, respectively. Patients receiving preoperative therapy showed a median OS of 26.0 months,1-, 3-, and 5-year OS rates were 75.5%, 48.4%, and 32.5%, respectively. There was no significant difference in the OS of patients with or without preoperative therapy (P>0.05). The median OS time of patients who received postoperative adjuvant therapy was 53.0 months, and the 1-, 3-, and 5-year OS rates were 87.9%, 59.2%, and 34.8%, respectively. The median OS time of patients who did not receive postoperative adjuvant therapy was 13.7 months, and 1-, 3-, and 5-year OS rates were 56.7%, 31.7%, and 22.4%, respectively (P<0.01). The median RFS of patients who received postoperative adjuvant therapy was 11.6 months, and the 1-, 3-, and 5-year RFS rates were 49.6%, 29.8%, and 26.8%, respectively. The median RFS of patients who did not receive postoperative adjuvant therapy was 4.2 months, and the 1-,3-,and 5-year RFS rates were 29.2%, 16.1%, and 12.5%, respectively (P<0.01). Multivariate analysis identified that maximum tumor diameter,postoperative adjuvant therapy,and treatment after recurrence were the independent predictors of the OS of patients with major vascular invasion and tumor thrombus (all P<0.05),while age,surgical approach,and postoperative adjuvant therapy independently influenced the RFS of patients with major vascular invasion and tumor thrombus(all P<0.05). Conclusions: HCC patients with vascular invasion/thrombus could benefit from surgery-based multimodal therapy after careful evaluation. Postoperative adjuvant therapy significantly reduces recurrence and prolongs patients' survival. 目的: 探讨合并大血管侵犯及癌栓的肝细胞癌(HCC)根治切除术后临床效果及患者围手术期治疗策略。 方法: 本研究为回顾性病例系列研究。回顾性分析2010年1月至2022年12月南京医科大学第一附属医院肝胆中心收治并行手术切除的387例HCC患者的临床和病理学资料。男性326例(84.2%),女性61例(15.8%);年龄[M(IQR)]54(16)岁(范围:16~82岁)。有大血管侵犯但无血管癌栓119例(30.7%),合并血管癌栓268例(69.3%)。采用Kaplan-Meier法绘制总体生存曲线和无复发生存曲线,使用单因素和多因素Cox回归模型分析患者的预后因素。 结果: 387例患者中,R0切除359例(92.8%),R1或R2切除28例(7.2%)。除院内死亡患者,354例R0切除患者中位生存时间为19.8个月,1、3、5年总体生存率分别为63.3%、35.1%、22.4%;中位无复发生存时间为5.6个月,1、3、5年无复发生存率分别为34.0%、18.0%、14.4%。行术前新辅助治疗患者中位生存时间为26.0个月,1、3、5年总体生存率分别为75.5%、48.4%、32.5%。术前是否行新辅助治疗对患者的总体生存无影响(P>0.05)。行术后辅助治疗患者的中位生存时间为53.0个月,1、3、5年总体生存率分别为87.9%、59.2%、34.8%,未行术后辅助治疗患者中位生存时间为13.7个月,1、3、5年总体生存率分别为56.7%、31.7%、22.4%(P<0.01)。行术后辅助治疗患者的中位无复发生存时间为11.6个月,1、3、5年无复发生存率分别为49.6%、29.8%、26.8%。未行术后辅助治疗患者中位无复发生存时间为4.2个月,1、3、5年无复发生存率分别为29.2%、16.1%、12.5%(P<0.01)。多因素分析结果显示,肿瘤最大径、术后辅助治疗和复发后处理方式是合并大血管侵犯及癌栓的HCC患者术后总体生存的独立影响因素(P值均<0.05);患者年龄、手术方式、术后辅助治疗是合并大血管侵犯及癌栓的HCC患者无复发生存的独立影响因素(P值均<0.05)。 结论: 合并大血管侵犯及癌栓的HCC患者在经过严格筛选及评估后,以手术切除为主的综合治疗可使患者生存获益,术后辅助治疗可减少术后肿瘤复发,延长患者生存时间。.

来源:Zhonghua Wai Ke Za Zhi,查看原文。版权归原作者所有。

引用

  1. Li CX, Zhang H, Chen RX, et al. [Analysis of clinical efficacy and perioperative treatment strategies after radical resection for hepatocellular carcinoma with major vascular invasion and tumor thrombus]. Zhonghua Wai Ke Za Zhi. 2025. PMID: 40831134. doi:10.3760/cma.j.cn112139-20250513-00256

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。